2023
Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis
Rhee T, Shim S, Popp J, Trikalinos T, Rosenheck R, Kellner C, Seiner S, Espinoza R, Forester B, McIntyre R. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Molecular Psychiatry 2023, 29: 750-759. PMID: 38123725, DOI: 10.1038/s41380-023-02366-8.Peer-Reviewed Original ResearchMajor depressive episodeStandardized mean differenceElectroconvulsive therapyAnesthetic agentsDepressive symptomsDepressive episodeRelative riskDiagnosis of MDESystematic reviewKetamine-treated patientsSafety of ketamineSerious adverse eventsResultsTwenty-two studiesMethodsPubMed/MEDLINEImportant clinical considerationsRandom-effects modelCognitive performanceAdverse eventsAntidepressant efficacyECT useTrials RegistryClinical efficacyCochrane LibraryWorse outcomesPatient profiles
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia